Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
, Encourages Investors with Losses to Contact Firm - EconoTimes)
NEW YORK, Sept. 29, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global shareholder rights litigation firm, has opened an investigation on behalf of investors in Zosano Pharma Corp (ZSAN). The investigation focuses on whether Zosano and certain of its executives and directors made false statements to investors about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
Investors who own Zosano stock are encouraged to contact Scott + Scott at (646)-582-0121 or email [email protected] to discuss their legal rights.
Scott + Scott, LLP is investigating potential violations of the federal securities laws in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”). In particular, the firm is investigating whether Zosano and certain of its executives and directors made false statements and omitted material information about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
What You Can Do
If you purchased shares of Zosano, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Joseph Halloran, Esq. by telephone at (646)-582-0121 or by email at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott, Attorneys at Law, LLP has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
Contact Scott + Scott, Attorneys at Law, LLP Joseph Halloran 646.582.0121 [email protected]
